252 results
Page 4 of 13
424B5
u1u400a5398
29 Jan 21
Prospectus supplement for primary offering
5:15pm
8-K
EX-99.1
716ugp 2z5n8c5yey
28 Jan 21
Updated Summary Business Information
4:26pm
424B5
aqhl 1qu5otrc4xgq7f2
28 Jan 21
Prospectus supplement for primary offering
4:08pm
8-K
EX-99.1
jdq0kx2twtjw
28 Jan 21
Adamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells from COVID-19 Patients
9:25am
8-K
kupnqxyz7ty71hk
28 Jan 21
Adamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells from COVID-19 Patients
9:25am
8-K
7f6we9uudntkv
22 Jan 21
SYMJEPI Products Now Available in the Walgreens Prescription Savings Club, with the Lowest Prices for Epinephrine Products
8:32am
8-K
EX-99.1
g7bljwn cpxr3s7ep
22 Jan 21
SYMJEPI Products Now Available in the Walgreens Prescription Savings Club, with the Lowest Prices for Epinephrine Products
8:32am
8-K
EX-99.1
gp34iry pu
20 Jan 21
Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19
5:06pm
8-K
lrirdps z85z8
20 Jan 21
Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19
5:06pm
8-K
e9axjqgqtmjhs
1 Dec 20
Adamis Pharmaceuticals Describes Planned Response to ZIMHI Complete Response Letter
5:04pm
8-K
EX-99.1
x716amv8kr7fgduy6a
1 Dec 20
Adamis Pharmaceuticals Describes Planned Response to ZIMHI Complete Response Letter
5:04pm
8-K
jygoz
16 Nov 20
Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHI
5:23pm
8-K
EX-99.1
asosm6du
16 Nov 20
Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHI
5:23pm
8-K
EX-99.1
j1fjx7svuu4jr
9 Nov 20
Adamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update
4:24pm
8-K
EX-99.2
62f76rw wkxmfz5d
5 Oct 20
Report of Independent Registered Public Accounting Firm
5:25pm
424B5
hom4m1dtky8x88dyps1o
21 Sep 20
Prospectus supplement for primary offering
6:03am
424B5
sj97uq0hd9qwb674ao
17 Sep 20
Prospectus supplement for primary offering
4:22pm
8-K
EX-99.1
m8qaagjg0edhpq tc
18 Aug 20
Adamis Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update
12:00am